ModifiedmhnPolicy CP.PMN.136

Mecamylamine (Vecamyl)

Defines medical necessity and prior authorization criteria for use of mecamylamine (Vecamyl) for adults with hypertension and other indications, and applies to members covered under specified Centene-affiliated lines of business.

Policy Summary

Payermhn

PolicyMecamylamine (Vecamyl)

Policy CodePolicy CP.PMN.136

Change TypeStep therapy bypass addedapproval duration extended

Effective DateJun 1, 2017

Next Review Date

Key ActionSubmit prior authorization demonstrating diagnosis of hypertension, age ≥18, and trials of three different-class antihypertensive agents unless exempt.

SourceLink

POLICY UPDATE CHANGES

Added step therapy bypass for Illinois HIM per IL HB 5395.

Extended initial approval duration from 6 to 12 months for this maintenance medication for a chronic condition and added ICHRA line of business.

12 monthsapproval duration (initial and continued therapy)

≥18minimum age for coverage

3required different-class agents trialed

2.5 mg BIDinitial dosing recommendation

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

policy effective year

Coverage Criteria

inv-01: Initial Approval — Hypertension

Covered when ALL of the following are met:

Hypertension initial approval: Member has a diagnosis of hypertension; member is ≥ 18 years old; failure of a combination of 3 formulary antihypertensive agents, each from different classes at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated.3 agents from different classes

For Illinois HIM requests, the step therapy requirements do not apply as of 1/1/2026 per IL HB 5395. Approval duration: 12 months.

inv-02: Continued Therapy — Hypertension

Covered when ALL of the following are met:

Continuation therapy: Member currently receiving medication via the Centene benefit or previously met initial approval criteria OR member currently receiving medication and enrolled in a state/product with continuity of care regulations; and member is responding positively to therapy.positive clinical response

Approval duration: 12 months.

inv-03: Other Indications / Off-label pathway

For other uses:

Other indications pathway: If the drug has undergone a recent label change (within the last 6 months) not yet reflected in this policy, refer to the specified formulary or non‑formulary policies for the relevant line of business (see policy numbers). Otherwise, if the requested use is not listed under section III and the label‑change clause does not apply, refer to the off‑label use policy for the relevant line of business (CP.CPA.09 for commercial, HIM.PA.154 for HIM/ICHRA, CP.PMN.53 for Medicaid).N/A

See listed policy numbers for Commercial, HIM/ICHRA, and Medicaid.

Non‑FDA approved indications that are not specifically addressed in this policy are not authorized for coverage unless the provider supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (see CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace/ICHRA, and CP.PMN.53 for Medicaid) or unless such uses are otherwise supported by evidence of coverage documents.

When coverage provisions in this clinical policy conflict with state Medicaid requirements, state Medicaid coverage provisions take precedence. Refer to the applicable state Medicaid manual for any specific coverage rules that apply to Medicaid members.

Use of this medication for non‑FDA approved (off‑label) indications without sufficient supporting documentation as required by the applicable off‑label use policies is not authorized (not medically necessary) under this policy.

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for treatment of hypertension. Provider must demonstrate the member has a diagnosis of hypertension, is age ≥ 18 years, and has failed a combination of three formulary antihypertensive agents from different classes at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated. Approval duration: 12 months.

See Appendix B for maximally indicated doses and Appendix D for rationale.
For Illinois HIM requests, the triple-agent step therapy requirement does not apply per IL HB 5395 (effective 01/01/2026).

Note

Prior Authorization Expectation

The clinical policy is intended as a guide to medical necessity to assist in making coverage decisions and administering benefits. It does not guarantee payment. Coverage decisions and administration of benefits are subject to all terms, conditions, exclusions, and limitations of the applicable coverage documents and Health Plan-level administrative policies and procedures.

Definitions

inv-16: Vecamyl (mecamylamine) — Key drug definition and indication summary

DrugVecamyl (mecamylamine)

Drug class / mechanismOral anti‑hypertensive agent; ganglion blocker

FDA‑approved indicationManagement of moderately severe to severe essential hypertension and uncomplicated malignant hypertension

Dosage forms noted in policy brief2.5 mg tablet; initial dosing recommendation 2.5 mg PO BID

Typical clinical roleUsed for adults with difficult‑to‑control or severe hypertension where prior agents have failed or are contraindicated

inv-17: Health Plan — Definition of Health Plan as used in this policy

Background

Mecamylamine (Vecamyl) is an oral ganglion blocker used as an anti‑hypertensive agent. It is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. The policy references guideline rationale supporting use of combination (triple‑agent) therapy for resistant or difficult‑to‑control hypertension when establishing prior authorization and step‑therapy requirements.

Revision History

2025-04-08material_change

Added step therapy bypass for Illinois HIM (per IL HB 5395), exempting IL HIM requests from the triple-agent step requirement effective 1/1/2026.

2026-03-30material_changeLatest

Extended initial approval duration from 6 to 12 months for this maintenance medication and added ICHRA line of business; approval durations for initial and continued therapy standardized to 12 months.

Policy Summary

Payermhn

PolicyMecamylamine (Vecamyl)

Policy CodePolicy CP.PMN.136

Change TypeStep therapy bypass addedapproval duration extended

Effective DateJun 1, 2017

Next Review Date

Key ActionSubmit prior authorization demonstrating diagnosis of hypertension, age ≥18, and trials of three different-class antihypertensive agents unless exempt.

SourceLink

On This Page

Step Therapy

Step Therapy Requirement

Step therapy requires failure of three antihypertensive agents from different classes at maximally indicated doses before authorization, unless contraindicated or clinically significant adverse effects occur.

IL HIM requests are exempt from the triple-agent step requirement per IL HB 5395; operational note added for provider guidance.

Documentation Required

Required Documentation / Denial Risk

Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria. Requests lacking documentation that the member meets the approval criteria (diagnosis, age, prior trials) or for non‑FDA indications without sufficient supporting evidence will be denied or not authorized.

Examples of acceptable documentation: office visit notes, blood pressure readings, medication trial records, lab results, and documented adverse reactions or contraindications.

Note

Follow Coverage Documents

Providers must follow the applicable coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance) and all Health Plan terms when submitting prior authorization requests and when providing care.

Note

Coverage Decisions and Administration of Benefits

Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents, as well as state and federal requirements and applicable Health Plan administrative policies and procedures.

Note

Provider-facing operational note: include all required documentation with the PA request. For Illinois HIM line of business, note the step therapy bypass when applicable.

A Health Plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or affiliates.

Policy roleMakes no representations about external content; provides guidance to medical necessity and assists with coverage decisions and benefit administration.

LimitationsDoes not constitute a contract, guarantee of payment, or medical advice; coverage decisions remain subject to coverage documents and applicable law.

Operational noteEffective date is determined by the Health Plan; posting date may differ from effective date and legal/regulatory requirements govern if discrepancies exist.